{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:27:38Z","timestamp":1790814458508,"version":"4.1.0"},"reference-count":20,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction characterised by an autoantibody against acetylcholine receptor (AChR-Ab), autoantibody against muscle-specific kinase (MuSK-Ab), lipoprotein-related protein 4 or agrin in the postsynaptic membrane at the neuromuscular junction. Many patients are resistant to conventional treatment and effective therapies are needed. Rituximab (RTX) is a monoclonal antibody directed against CD20 antigen on B cells which has been successfully employed in anti-MuSK-Ab+MG, but the efficacy in anti-AChR-Ab+MG is still debated. The purpose of this systematic review was to describe the best evidence for RTX in the acetylcholine receptor subtype. The authors undertook a literature search during the period of 1999\u20132019 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analys methodology, employing (myasthenia)+(gravis)+(RTX) as search terms. The analysis was confined to studies that include at least five patients with confirmed anti-AChR-Ab+MG. Thirteen studies have been selected, showing a good safety. The data obtained were heterogeneous in terms of posology, administration scheme and patients\u2019 evaluation, ranging from a minimum of two to a maximum of three cycles. RTX led to a sustained clinical improvement with prolonged time to relapse, in parallel to a reduction or discontinuation of other immunosuppressive therapies. Treatment with RTX appears to work in some but not all patients with anti-AChR-Ab+MG, but randomised controlled trials are needed. Future studies should take into account the subtype of MG and employ reliable measures of outcome and severity focusing on how to identify patients who may benefit from the treatment. Trial registration number: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02110706\">NCT02110706<\/jats:ext-link>.<\/jats:p>","DOI":"10.1136\/jnnp-2019-322606","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T22:19:35Z","timestamp":1582669175000},"page":"392-395","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":86,"title":["Rituximab in AChR subtype of myasthenia gravis: systematic review"],"prefix":"10.1136","volume":"91","clinical-trial-number":[{"clinical-trial-number":"nct02110706","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9805-1655","authenticated-orcid":false,"given":"Vincenzo","family":"Di Stefano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Lupica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna Gabriella","family":"Rispoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Muzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Brighina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"key-10.1136\/jnnp-2019-322606-1","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.nmd.2019.06.002","article-title":"Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis","volume":"29","author":"Roda","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"key-10.1136\/jnnp-2019-322606-2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to Rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"key-10.1136\/jnnp-2019-322606-3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.17712\/nsj.2019.3.20190011","article-title":"Clinical features and outcomes of patients with myasthenia gravis","volume":"24","author":"Alanazy","year":"2019","journal-title":"Neurosciences"},{"key":"key-10.1136\/jnnp-2019-322606-4","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodr\u00edguez Cruz","year":"2015","journal-title":"JAMA Neurol"},{"key":"key-10.1136\/jnnp-2019-322606-5","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1212\/NXI.0000000000000357","article-title":"IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG","volume":"4","author":"Huda","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"key-10.1136\/jnnp-2019-322606-6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve"},{"key":"key-10.1136\/jnnp-2019-322606-7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.nmd.2016.12.004","article-title":"Resistant myasthenia gravis and rituximab: a monocentric retrospective study of 28 patients","volume":"27","author":"Afanasiev","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"key-10.1136\/jnnp-2019-322606-8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/CND.0000000000000257","article-title":"Impact of refractory myasthenia gravis on health-related quality of life","volume":"20","author":"Boscoe","year":"2019","journal-title":"J Clin Neuromuscul Dis"},{"key":"key-10.1136\/jnnp-2019-322606-9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","article-title":"Use and monitoring of low dose rituximab in myasthenia gravis","volume":"82","author":"Blum","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2019-322606-10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ajh.20169","article-title":"Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma","volume":"77","author":"Gajra","year":"2004","journal-title":"Am J Hematol"},{"key":"key-10.1136\/jnnp-2019-322606-11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor Autoantibody-Positive myasthenia gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol"},{"key":"key-10.1136\/jnnp-2019-322606-12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","article-title":"Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis","volume":"311","author":"Jing","year":"2017","journal-title":"J Neuroimmunol"},{"key":"key-10.1136\/jnnp-2019-322606-13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2019-322606-14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2019-322606-15","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419871187","article-title":"Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis","volume":"12","author":"Choi","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"key-10.1136\/jnnp-2019-322606-16","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2019-322606-17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3233\/JND-180300","article-title":"Efficacy of rituximab in refractory generalized anti-AChR myasthenia gravis","volume":"5","author":"Landon-Cardinal","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"key-10.1136\/jnnp-2019-322606-18","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up","volume":"3","author":"Anderson","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"key-10.1136\/jnnp-2019-322606-19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/mus.25529","article-title":"QMG and MG-ADL correlations: study of eculizumab treatment of myasthenia gravis","volume":"56","author":"Howard","year":"2017","journal-title":"Muscle Nerve"},{"key":"key-10.1136\/jnnp-2019-322606-20","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.21037\/atm.2019.06.65","article-title":"MGTX extension study longitudinally favors early thymectomy in non-thymomatous young-adult patients with AChR antibody-positive myasthenia gravis","volume":"7","author":"Akaishi","year":"2019","journal-title":"Ann Transl Med"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2019-322606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T04:51:15Z","timestamp":1601095875000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2019-322606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,3,16]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/jnnp-2019-322606"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2019-322606","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,25]]}}}